ION455
/ Ionis
- LARVOL DELTA
Home
Next
Prev
1 to 18
Of
18
Go to page
1
May 10, 2024
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH.
(clinicaltrials.gov)
- P1 | N=40 | Terminated | Sponsor: AstraZeneca | N=60 ➔ 40 | Trial completion date: Oct 2024 ➔ Mar 2024 | Recruiting ➔ Terminated; AstraZeneca have decided to not move forward with the development of the compound.
Enrollment change • Trial completion date • Trial termination • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis
April 30, 2024
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD7503 in Japanese Healthy Participants.
(clinicaltrials.gov)
- P1 | N=12 | Completed | Sponsor: AstraZeneca | Active, not recruiting ➔ Completed
Trial completion
March 18, 2024
Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease
(clinicaltrials.gov)
- P1 | N=19 | Completed | Sponsor: AstraZeneca | Active, not recruiting ➔ Completed
Trial completion • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease
February 09, 2024
Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease
(clinicaltrials.gov)
- P1 | N=19 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting
Enrollment closed • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease
December 26, 2023
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD7503 in Japanese Healthy Participants.
(clinicaltrials.gov)
- P1 | N=12 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting
Enrollment closed
November 29, 2023
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD7503 in Japanese Healthy Participants.
(clinicaltrials.gov)
- P1 | N=11 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting
Enrollment open
October 23, 2023
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD7503 in Japanese Healthy Participants
(clinicaltrials.gov)
- P1 | N=12 | Not yet recruiting | Sponsor: AstraZeneca
New P1 trial
September 15, 2023
Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease
(clinicaltrials.gov)
- P1 | N=20 | Recruiting | Sponsor: AstraZeneca | N=14 ➔ 20
Enrollment change • Hepatology • Non-alcoholic Fatty Liver Disease • Non-alcoholic Steatohepatitis
August 28, 2023
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH.
(clinicaltrials.gov)
- P1 | N=60 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Jun 2024 ➔ Oct 2024
Trial completion date • Hepatology • Non-alcoholic Steatohepatitis
July 03, 2023
Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease
(clinicaltrials.gov)
- P1 | N=14 | Recruiting | Sponsor: AstraZeneca | Active, not recruiting ➔ Recruiting | Trial completion date: Jan 2023 ➔ Dec 2023 | Trial primary completion date: Jan 2023 ➔ Dec 2023
Enrollment open • Trial completion date • Trial primary completion date • Hepatology • Non-alcoholic Fatty Liver Disease • Non-alcoholic Steatohepatitis
May 18, 2023
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH.
(clinicaltrials.gov)
- P1 | N=60 | Recruiting | Sponsor: AstraZeneca
New P1 trial • Hepatology • Non-alcoholic Steatohepatitis
January 17, 2023
Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease
(clinicaltrials.gov)
- P1 | N=8 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting | Trial completion date: Aug 2023 ➔ Jan 2023 | Trial primary completion date: Aug 2023 ➔ Jan 2023
Enrollment closed • Trial completion date • Trial primary completion date • Hepatology • Non-alcoholic Fatty Liver Disease • Non-alcoholic Steatohepatitis
December 08, 2022
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7503 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=56 | Completed | Sponsor: AstraZeneca | Active, not recruiting ➔ Completed
Trial completion
November 18, 2022
Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease
(clinicaltrials.gov)
- P1 | N=5 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Mar 2023 ➔ Aug 2023 | Trial primary completion date: Mar 2023 ➔ Aug 2023
Trial completion date • Trial primary completion date • Hepatology • Non-alcoholic Fatty Liver Disease • Non-alcoholic Steatohepatitis
September 29, 2022
Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease
(clinicaltrials.gov)
- P1 | N=5 | Recruiting | Sponsor: AstraZeneca
New P1 trial • Hepatology • Non-alcoholic Fatty Liver Disease • Non-alcoholic Steatohepatitis
September 26, 2022
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7503 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=56 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting | Trial completion date: Feb 2023 ➔ Nov 2022
Enrollment closed • Trial completion date
September 24, 2022
"Does not bode well for NASH assets ION839 and ION455🤔 🤞"
(@dr_muniyappa)
Hepatology • Non-alcoholic Steatohepatitis
August 17, 2022
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7503 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=72 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Nov 2022 ➔ Feb 2023
Trial completion date
1 to 18
Of
18
Go to page
1